The ADA COVID-19 and Diabetes Research Awards are intended to support basic, translational, or clincical studies focusing on the impact of diabetes on COVID-19 and the impact of COVID-19 on diabetes and its complications.
For the purposes of this award, basic research is defined as investigation into the fundamental cellular, molecular and biochemical mechanisms underlying the development, detection, treatment and management of COVID-19 in diabetes and its complications.
Clinical research is defined as research where the effect of COVID-19 in diabetes and its complications is evalu-ated, and includes therapeutic interventions, health services/care delivery research and epidemiological re-search aimed at identifying the distribution and determinants of disease in a population.
Translational research supported through this mechanism will typically involve expertise, collaboration and en-gagement across disciplines, and falls into two broad categories, (1) translating basic biological discoveries on of COVID-19 in diabetes and its complications from the laboratory into clinical applications that improve human health, and (2) accelerating the translation of clinical advances from research on of COVID-19 in diabetes and its complications to the community setting or enhancing the adoption of best practices in patient care.
Recent clinical results have shown that people with diabetes are at higher risk of death from COVID-19 and that COVID-19 drives an increased risk of hyperglycemia and other complications in those with and without diabetes. This is in addition to the risk due to advanced age and chronic disease. Both the biological mechanisms underlying this risk and how to minimize it remain poorly understood. There is an urgent need for research to understand the impact of diabetes on COVID-19 and vice versa. This is true at a basic and clinical level.
The main text of the application will be a two-page application to provide all necessary study components (Aims, Significance, Preliminary data (if applicable), Research Plan, Expected Actionable Outcomes) with a one-page listing of critical references, PI Biosketch, and budget form.
The goal of this RFA is to use a rapid application and review process to identify at least 10 grants of up to $100,000/each in this area and of high scientific merit for immediate funding.
The COVID-19 and Diabetes Research Awards call for applications will open Monday, May 11, 2020.
The expedited application deadline will be 5pm ET on May 22, 2020 for July 1, 2020 funding.
URLs for more information:
- Application Instructions(link is external)
- Budget Form
- Table of Contents Template
- ORCiD iD required, register online at orcid.org(link is external)
Online Application (Expedited Deadline: 5pm ET on May 22, 2020)
Filed Under: Funding Opportunities